Braveheart Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BRVE Nasdaq 2836 www.braveheart.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Braveheart Bio, Inc.

Braveheart Bio to Participate in Stifel Cardiometabolic Forum - Sep 16th, 2026 2:30 pm
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - Sep 8th, 2026 2:03 pm
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’ - Sep 8th, 2026 12:01 pm
Braveheart Bio to Participate in Cantor Global Healthcare Conference - Sep 1st, 2026 2:30 pm
Insiders Are Betting Big on These 3 Healthcare Stocks - Aug 31st, 2026 11:20 am
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls - Aug 31st, 2026 7:45 am
Jefferies starts biopharma firm Braveheart at Buy after IPO - Aug 31st, 2026 5:00 am
Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO - Aug 11th, 2026 2:08 pm
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Aug 7th, 2026 2:05 pm
Braveheart Bio Announces Pricing of Upsized Initial Public Offering - Aug 5th, 2026 8:33 pm